Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Edwards Lifesciences EW in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 3 | 4 | 1 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 1 | 0 |
| 2M Ago | 3 | 1 | 3 | 0 | 0 |
| 3M Ago | 1 | 1 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $78.5, along with a high estimate of $94.00 and a low estimate of $57.00. Observing a downward trend, the current average is 11.62% lower than the prior average price target of $88.82.
Analyzing Analyst Ratings: A Detailed Breakdown
The perception of Edwards Lifesciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Richard Newitter | Truist Securities | Raises | Buy | $84.00 | $78.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $78.00 | $76.00 |
| Patrick Wood | Morgan Stanley | Lowers | Overweight | $80.00 | $102.00 |
| Mike Polark | Wolfe Research | Announces | Underperform | $57.00 | - |
| Rick Wise | Stifel | Lowers | Hold | $70.00 | $87.00 |
| Anthony Petrone | Mizuho | Lowers | Buy | $85.00 | $90.00 |
| Richard Newitter | Truist Securities | Lowers | Buy | $76.00 | $83.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $82.00 | $86.00 |
| Adam Maeder | Piper Sandler | Lowers | Neutral | $68.00 | $83.00 |
| Joanne Wuensch | Citigroup | Lowers | Buy | $85.00 | $94.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Equal-Weight | $75.00 | $88.00 |
| Mike Kratky | Leerink Partners | Announces | Market Perform | $75.00 | - |
| Joanne Wuensch | Citigroup | Lowers | Buy | $94.00 | $110.00 |
| Suraj Kalia | Oppenheimer | Announces | Outperform | $90.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edwards Lifesciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Edwards Lifesciences's stock. This examination reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Edwards Lifesciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
Get to Know Edwards Lifesciences Better
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
Breaking Down Edwards Lifesciences's Financial Performance
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Edwards Lifesciences showcased positive performance, achieving a revenue growth rate of 12.27% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Edwards Lifesciences's net margin excels beyond industry benchmarks, reaching 25.99%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Edwards Lifesciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.91%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Edwards Lifesciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.19% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average. With a ratio of 0.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
What Are Analyst Ratings?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
